Welcome to
Prosigna is 510(k) cleared and CE marked. Prosigna is available to healthcare professionals in the United States, in markets that recognize the CE mark, and/or in which Prosigna is registered.
I am a healthcare professional in the US
I am a healthcare professional outside the US

Now included 4 Clinical Practice Guidelines

Home
This site is intended for US residents only.

Prosigna is powered by nCounter® digital technology1

Prosigna sets the standard for reliable, reproducible results1,2

Since 2008, NanoString’s nCounter technology has been changing the way researchers study gene expression. Now we are applying the same technology that has led to hundreds of peer-reviewed publications to breast cancer diagnostics. Fully automated and easy to use, the nCounter-based Prosigna assay allows you to quickly and accurately analyze breast cancer gene expression and make informed treatment decisions.

  • Strong analytical performance: sensitive, precise, and quantitative
  • Single-tube multiplexing: all 50 Prosigna genes are measured in a single reaction—no amplification required
  • Easy to use: fully automated, intuitive user interface
Nature Biotech cover

Nature Biotechnology features the nCounter technology

VIEW THE ARTICLE

Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.
References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Nielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens [published online ahead of print March 13, 2014]. BMC Cancer. doi:10.1186/1471-2407-14-177. 3. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.